financetom
Business
financetom
/
Business
/
Here’s what experts have to say on Maharashtra COVID-19 situation, fresh curbs and Amravati lockdown
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Here’s what experts have to say on Maharashtra COVID-19 situation, fresh curbs and Amravati lockdown
Feb 22, 2021 4:08 AM

Maharashtra chief minister Uddhav Thackeray has warned that the lockdown would have to be reimposed if daily COVID-19 cases continue to rise and if the citizenry doesn’t cooperate in terms of disciplined behaviour. He has also warned the people to follow the protocol and thereby avoid the lockdown. Meanwhile, a week’s lockdown has been imposed in the Amravati district.

In an interview with CNBC-TV18, Shashank Joshi, Member of Maharashtra COVID Task Force and Pradeep Awate, Maharashtra Surveillance Officer spoke at length about the curbs reimposed.

“Doubling of the COVID cases in Mumbai in one week is worrisome and also opening up of local trains and more social gatherings has caused a spike in cases. There was a basic tendency of unmasking; people were not masking appropriately and that led to an exponential double rise,” said Joshi.

Speaking further about the cases, Joshi added, “As far as Mumbai is concerned, I think it is still a yellow signal but if people do not take a step back and reappropriate and recalibrate their behavioural pattern then we would probably head for what we headed exactly a year back.”

On the mutation front, he said, “It’s unlikely that there are any foreign strains. If at all there is a mutant, it could be more transmissible. The suspicion went up only because the test positivity rate of Amravati went up to 50 percent.”

Meanwhile, Awate said, “Seven out of 10 areas with rising COVID cases are from the Vidarbha district. As Dr. Joshi mentioned, basically there is lethargy regarding COVID appropriate behaviour among the masses and it is observed in family functions like weddings or parties.”

For full discussion, watch the video

(Edited by : Ajay Vaishnav)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved